Emergent BioSolutions
Public-health oriented company that researches, develops, manufactures and distributes medical countermeasures and protective products. Operates multi-site biologics and sterile-product manufacturing with containment capabilities, provides contract development and scale-up services, supports government stockpiles and emergency response logistics, and funds externally sponsored research and public-health education programs.
Industries
Nr. of Employees
large (251-1000)
Emergent BioSolutions
Patents
Products
ANTHRASIL
Anthrax Immunoglobulin (Human) Injection Sterile Solution for Infusion indicated for the treatment of adult and pediatric patients with toxemia associated with inhalational anthrax.
BioThrax
Anthrax Vaccine Adsorbed Suspension for Injection, Anthrax Antigen Filtrate 50 micrograms per 0.5 mL dose, indicated for the active immunization for the prevention of disease caused by Bacillus anthracis.
CYFENDUS
CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) is a suspension for intramuscular injection indicated for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs.
BAT
Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine) is a sterile solution for intravenous injection indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G.
VIGIV
VIGIV (vaccinia immune globulin intravenous, human), 5% solution for intravenous use, indicated for the treatment of complications due to vaccinia vaccination.
Raxibacumab
Raxibacumab injection is a monoclonal antibody indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax.
ANTHRASIL
Anthrax Immunoglobulin (Human) Injection Sterile Solution for Infusion indicated for the treatment of adult and pediatric patients with toxemia associated with inhalational anthrax.
BioThrax
Anthrax Vaccine Adsorbed Suspension for Injection, Anthrax Antigen Filtrate 50 micrograms per 0.5 mL dose, indicated for the active immunization for the prevention of disease caused by Bacillus anthracis.
CYFENDUS
CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) is a suspension for intramuscular injection indicated for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs.
BAT
Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine) is a sterile solution for intravenous injection indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G.
VIGIV
VIGIV (vaccinia immune globulin intravenous, human), 5% solution for intravenous use, indicated for the treatment of complications due to vaccinia vaccination.
Raxibacumab
Raxibacumab injection is a monoclonal antibody indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax.
Services
Contract development, process optimization, technology transfer, drug substance manufacture, aseptic fill/finish, analytical testing and packaging for clinical and commercial programs across North America.
Funding and operational support for investigator-initiated and collaborative research and medical education, including product provision for studies, medical writing, data management and statistical analysis assistance.
Commercial distribution, donation coordination with nonprofit partners and managed supply to community organizations, first responders and government entities for opioid emergency preparedness products (including naloxone formulations).
Contract development, process optimization, technology transfer, drug substance manufacture, aseptic fill/finish, analytical testing and packaging for clinical and commercial programs across North America.
Funding and operational support for investigator-initiated and collaborative research and medical education, including product provision for studies, medical writing, data management and statistical analysis assistance.
Commercial distribution, donation coordination with nonprofit partners and managed supply to community organizations, first responders and government entities for opioid emergency preparedness products (including naloxone formulations).
Expertise Areas
- Clinical trial design and execution
- Biologics and plasma therapeutics manufacturing
- Aseptic fill/finish and sterile processing
- Process development and technology transfer
Key Technologies
- Aseptic robotic isolator filling systems
- BSL2/BSL3 containment operations
- Polyclonal antibody production and plasma fractionation
- Therapeutic protein manufacturing
News & Updates
Announcement of a contract modification related to a botulism antitoxin program.
Announcement of a strategic manufacturing partnership to support manufacturing and distribution arrangements for a vaccine.
Launch of a public education campaign focused on opioid emergency preparedness and naloxone awareness.
Media statement describing continued partnerships and education efforts focused on recovery and overdose prevention.
Public statement supporting provincial legislative efforts to increase naloxone access in public spaces.
Company statement regarding the resolution of a regulatory investigation related to legacy matters.
Announcement of a contract modification related to a botulism antitoxin program.
Announcement of a strategic manufacturing partnership to support manufacturing and distribution arrangements for a vaccine.
Launch of a public education campaign focused on opioid emergency preparedness and naloxone awareness.
Media statement describing continued partnerships and education efforts focused on recovery and overdose prevention.
Public statement supporting provincial legislative efforts to increase naloxone access in public spaces.
Company statement regarding the resolution of a regulatory investigation related to legacy matters.